Here are 16 key notes on orthopedic and spine device companies over the past week.
Amedica is now in compliance with NASDAQ listing requirements after a period last year where the company's share price dipped below $1.
The FDA tentatively scheduled a meeting of the Orthopaedic and Rehabilitation Devices Panel to review Cartiva's premarket approval application for its Cartiva Synthetic Cartilage Implant.
Ellipse Technologies withdrew its initial public offering.
Histogenics enrolled 123 of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial.
Implanet hired Brian T. Ennis as president of Implanet America.
Neurosurgery published a peer-reviewed article regarding the cost-effectiveness of LDR's Mobi-C Cervical Disc.
Misonix reported net sales of $6 million for the second quarter of fiscal year 2016, ending Dec. 31, 2015.
MX Orthopedics received FDA clearance for its dynaMX Compression Staple.
OrthAlign entered into a multi-country distribution agreement with Smith & Nephew.
There are two new economic publications showing the cost-effectiveness of minimally invasive sacroiliac joint fusion with SI-BONE's iFuse Implant System.
Stryker plans to acquire Synergetics USA's neuro portfolio.
Tissue Regenix appointed Drew Distin as vice president of its recently established subsidiary, Tissue Regenix Orthopaedic, North America.
Tyber Medical released its TyWedge Osteotomy Wedge Systems.
David Greenwald, MD, successfully implanted the 1st patent-pending VerteLP Lateral Lumber Cage from VGI Medical.
The FDA granted clearance for Wenzel Spine's new stand-along expandable lumbar interbody fusion device.
Some of Zimmer Biomet's shareholders affiliated with Blackstone and Goldman Zachs plan to offer more than 11 million common stock shares for sale.